Osteoprotegerin increases parallel to insulin resistance in obese adolescents-Reference-Cited by-同舟云学术

Osteoprotegerin increases parallel to insulin resistance in obese adolescents

Published:2018-06-07 Issue:1-2 Volume:44 Page:9-15
ISSN:0743-5800
Container-title:Endocrine Research
language:en
Short-container-title:Endocrine Research

Author:

Kotanidou Eleni P.¹^ORCID,Kotanidis Christos P.¹,Giza Styliani¹,Serbis Anastasios¹,Tsinopoulou Vasiliki-Regina¹,Karalazou Paraskevi²,Tzimagiorgis Georgios²,Galli-Tsinopoulou Assimina¹

Affiliation:

1. 4th Department of Pediatrics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Papageorgiou General Hospital, Thessaloniki, Greece

2. Laboratory of Biological Chemistry, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece

Funder

Research in pediatric diabetes, research committee of Aristotle University of Thessaloniki

Research Committee, Aristotle University of Thessaloniki

Publisher

Informa UK Limited

Subject

Endocrinology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/07435800.2018.1480630

Reference30 articles.

1. Childhood obesity trends from primary care electronic health records in England between 1994 and 2013: population-based cohort study

2. Estrogen Inhibits Vascular Calcification via Vascular RANKL System

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the Link between Oxidative Stress, Selenium Levels, and Obesity in Youth;International Journal of Molecular Sciences;2024-07-02

2. RANKL signaling drives skeletal muscle into the oxidative profile;Journal of Bone and Mineral Research;2024-04-15

3. Value of serum osteoprotegerin in the assessment of endothelial dysfunction in obesity;The Egyptian Journal of Internal Medicine;2024-04-05

4. OSTEOPROTEGERIN AND RECEPTOR ACTIVATOR OF THE NUCLEAR FACTOR KAPPA B LIGAND (RANKL) IN HEALTHY PUBERTAL GIRLS- RELATIONSHIPS WITH PHYSICAL GROWTH AND CLASSICAL BONE TURNOVER MARKERS;J PHYSIOL PHARMACOL;2024

5. Osteoprotegerin/Receptor Activator of Nuclear Factor-Kappa B Ligand/Receptor Activator of Nuclear Factor-Kappa B Axis in Obesity, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease;Current Obesity Reports;2023-05-19